Immunogenetics of prostate cancer: A still unexplored field of study

Eva Dreussi, Fabrizio Ecca, Lucia Scarabel, Sara Gagno, Giuseppe Toffoli

Research output: Contribution to journalReview articlepeer-review

Abstract

The immune system is a double-edged sword with regard to the prostate cancer (PCa) battle. Immunogenetics, the study of the potential role of immune-related polymorphisms, is taking its first steps in the treatment of this malignancy. This review summarizes the most recent papers addressing the potential of immunogenetics in PCa, reporting immune-related polymorphisms associated with tumor aggressiveness, treatment toxicity and patients' prognosis. With some peculiarities, RNASEL, IL-6, IL-10, IL-1β and MMP7 have arisen as the most significant biomarkers in PCa treatment and management, having a potential clinical role. Validation prospective clinical studies are required to translate immunogenetics into precision treatment of PCa.

Original languageEnglish
Pages (from-to)263-283
Number of pages21
JournalPharmacogenomics
Volume19
Issue number3
DOIs
Publication statusPublished - Feb 1 2018

Keywords

  • immune system
  • polymorphisms
  • prostate cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Immunogenetics of prostate cancer: A still unexplored field of study'. Together they form a unique fingerprint.

Cite this